Vaijayanti Gupta (PhD, University of Maryland, College Park and Syngenta) is a molecular biologist who trained in Genetics and Genomics at National Institutes of Health, USA. She has worked on several cutting edge technology platforms and analysis, including microarrays, Next-Gen Sequencing, droplet digital PCR and multi-omics.
Vaijayanti’s career spans two decades in healthcare and diagnostics. She has led teams involved in the development of laboratory developed tests (LDTs) for clinical diagnostics, including liquid biopsy-based detection of cancer, from assays to market. Her current research is focused on the emerging area of CRISPR based technologies and their clinical applications.